Rodney A. Brown MRPharmS: President
Rodney is the President and Founding Director of PharmaNova Inc. He was also the founder and Principal of PharmaNova Consulting, which provided consulting and training services for the pharmaceutical industry and from which stems the current organization. In a career devoted to the discovery and development of new medicines, his industry experience spans pharmaceutical R&D and, as a pharmacologist and Head of Cardiovascular Research at Fisons Pharmaceuticals, UK, he led numerous projects from concept to clinic. With hands-on-experience in multiple sectors of health care, he established and directed project management in discovery research and clinical development in 3 US organizations and the Discovery Project Office as the hub of Research Coordination and Knowledge Management at Astra Arcus USA, and was Head of Scientific Operations and Project Management at AstraZeneca (Neuroscience) R&D Boston. A seasoned industry professional experienced in multiple therapeutic areas, Rodney has managed international development projects through NDA in UK, Europe & North America. He is an author and inventor on numerous scientific papers and patents. Rodney trained in the UK (University of London B.Pharm., MRPharmS.). He is a former Board Director of the High Tech Business Council of Rochester, NY and a founding member of the Rochester NY BioCluster. His goal for PharmaNova is for the Company to become an internationally recognized leader in the field of pharmaceutical nanoparticle technology and to become successful in worldwide commercialization of medically important new product opportunities derived from PharmaNova’s NovaSperse℠ and associated technologies.
Vivienne H. Brown: Founder & Director, Business Management and Administration
A co-founder of PharmaNova, Inc., Vivienne is also a Company Officer, being Secretary and Treasurer to the Board of Directors. She is also a Founder and Board Director of PharmaNova Europa, Ltd., PharmaNova’s affiliate company in the UK/Europe. Vivienne has held numerous administrative and senior management positions in companies including transport manager of a heavy haulage company, helping to bring the business from a division of a plant hire company to a highly successful independent business (Tracton, Ltd.). Joining two other entrepreneurs in 1975 she helped grow a gas controls company from inception to a multi-million £UK enterprise (Seagas, Ltd.) in 4 years. Seagas continues to thrive on the manufacture, import/export and distribution of gas control systems. Her experience in understanding and managing the needs of smaller organizations to successfully maintain the business and facilitate growth are a perfect match for PharmaNova as it transitions through the point of inflection to true organic growth. A natural multi-tasker, Vivienne directs and manages the accounts, benefits, HR, purchasing, insurance and general procedures, interfacing closely with all business units and personnel. Her goal for PharmaNova is to help create a solid structure for lasting growth.
Deepak Thassu Ph.D., MBA. Scientific Advisor
Deepak has over 20 years of pharmaceutical product development experience in Research and Development of leading pharmaceutical companies of the world. He is specialized in the fields of Nanotechnology and Novel Drug Delivery Systems with emphasis on parenteral and ophthalmic delivery systems for bio/pharmaceuticals. Deepak is an inventor on multiple US and EU drug delivery and formulation patents and is the author and/or editor of several books and book chapters. His first book in the area of (pharmaceutical) nanotechnology, “Nanoparticulate Drug Delivery Systems,” was published in 2007 (Taylor & Francis). In March 2010, Deepak's latest book, "Ocular Drug Delivery System: Barriers and Applications of Nanoparticulate Systems" was accepted for publication (Taylor & Francis). During his global career he has held several leadership positions: He was Chief Scientific Officer and Senior Vice President Product Development at Holopack International. Columbia, SC., and with UCB Inc and Celltech Americas he was Associate Director Global Product Technology Development and led several extended release technology and product development projects from concept to clinic. Deepak holds degrees in Pharmacy, PhD in Pharmaceutics, and MBA from Cornell University.
Drug Delivery Nanoparticles Formulations and Characterization, Drugs and the Pharmaceutical Sciences Yashwant Pathak & Deepak Thassu (Eds) Vol 191 New York, Informa Healthcare USA, 2009
Thomas C. Parker, Vice President, Commercial Affairs
Tom serves as Vice President, Commercial Affairs of PharmaNova, Inc. and is experienced in building commercial teams, strategic planning and launching pharmaceutical products in various therapeutic categories including branded and generic prescription products. Prior to co-founding PharmaNova, Tom was General Manager for Collateral Pharmaceuticals/Therapeutics, a San Diego based cardiovascular gene therapeutics company that was acquired by Schering AG in 2002. Prior to Collateral Therapeutics, Tom was Sr. VP, Marketing & Sales and Business Development for Celltech Americas and also previously held senior management positions at Fisons Pharmaceuticals and Medeva USA. Tom attended the University of Tennessee and holds a B.S./B.A. and is a graduate of the John Anderson Graduate School of Management at UCLA, Medical Marketing Program.
Mostafa Analoui, Ph.D., Director
Dr. Analoui was elected to the PharmaNova Board of Directors in July, 2012. Dr. Analoui is Head of Healthcare and Life Sciences at The Livingston Group (New York, NY) and Chairman and CEO of Cense Biosciences, Inc. Previously he was the Senior Director at Pfizer Global Research and Development. He is also adjunct Professor of Oral Pathology, Medicine and Radiology at Indiana University. Dr. Analoui is actively involved in investment, management and scientific/business development of nanotechnology, drug discovery/development, diagnostic imaging, and global strategies. While at Pfizer, he was the Site Head for Global Clinical Technology in Groton and New London, a division focusing on emerging technologies for development and validation of biomarkers and diagnostics for drug development. Prior to joining Pfizer, Dr. Analoui was the Director of Oral and Maxillofacial Imaging Research, Associate Professor of Radiology at Indiana University, and Associate Professor of Biomedical Engineering and Electrical & Comp Engineering at Purdue University. He was also President and CEO of Therametric Technology Inc. He has received his Ph.D. from Purdue University, followed by Post-Doctoral Fellowship at IBM TJ Watson Research Center in NY.
In addition to industry leadership in biomedical and technology fields, he consults and lectures in US, Europe and Asia. He has also served on various scientific, regulatory, and business advisory committees and boards, including NIH, NSF, PhRMA, NASA, and OECD. Dr. Analoui has authored over 130 publications, including journal articles, book chapters, and technical reports. He is senior member of IEEE, SPIE, and RSNA. He also serves as board member of VirtualScopics (Nasdaq: VSCP), Calando Pharmaceutical (Nasdaq: ARWR), BEACON (Biomedical Engineering Alliance and Consortium) and NanoBusiness Alliance.